Literature DB >> 3379435

Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate.

S Noda1, H Umezaki, K Yamamoto, T Araki, T Murakami, N Ishii.   

Abstract

Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate. The clinical, biochemical, and pathological picture was similar to Reye's syndrome. Calcium hopantenate is a pantothenic acid antagonist. The serum levels of calcium hopantenate were high in coma, and that of pantothenic acid examined in one patient was lowered. Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3379435      PMCID： PMC1032980          DOI： 10.1136/jnnp.51.4.582

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

1.  Human pantothenic acid deficiency produced by omega-methyl pantothenic acid.

Authors:  R E HODGES; W B BEAN; M A OHLSON; R BLEILER
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. A DISEASE ENTITY IN CHILDHOOD.

Authors:  R D REYE; G MORGAN; J BARAL
Journal:  Lancet       Date:  1963-10-12       Impact factor: 79.321

3.  Studies on pantothenic acid antagonists.

Authors:  H ARIYAMA; S KIMURA
Journal:  J Vitaminol (Kyoto)       Date:  1960-03-10

4.  Studies of pantothenic acid metabolism.

Authors:  R LUBIN; K A DAUM; W B BEAN
Journal:  Am J Clin Nutr       Date:  1956 Jul-Aug       Impact factor: 7.045

5.  Relation of pantothenic acid to adrenal cortical function.

Authors:  E P RALLI; M E DUMM
Journal:  Vitam Horm       Date:  1953       Impact factor: 3.421

6.  Metabolic functions of pantothenic acid.

Authors:  G D NOVELLI
Journal:  Physiol Rev       Date:  1953-10       Impact factor: 37.312

7.  Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera).

Authors:  J C Partin; W K Schubert; J S Partin
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

8.  Effect of gamma-aminobutyric acid derivatives, especially homopantothenic acid, on the excitability of the brain.

Authors:  Y Nishizawa; T Kodama; G Tsujino
Journal:  J Vitaminol (Kyoto)       Date:  1968-12-10

9.  Letter: Reye's syndrome of children and the fatty-liver-and-kidney syndrome of chickens.

Authors:  P A Wight; W G Siller; A J Evans; D W Bannister; C C Whitehead; R Blair
Journal:  Lancet       Date:  1975-06-14       Impact factor: 79.321

10.  [3 cases of acute encephalopathy associated with calcium hopantenate administration].

Authors:  T Sugimoto; A Yasuhara; N Nishida; Y Sakane; Y Sugimoto
Journal:  No To Hattatsu       Date:  1983
  10 in total
  2 in total

1.  Development of HTLV-I associated myelopathy (HAM) in a seroconverted patient for antibody to HTLV-I.

Authors:  Y Sakai; H Yao; S Sadoshima; M Fujishima; K Okochi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

2.  The Coenzyme A Level Modulator Hopantenate (HoPan) Inhibits Phosphopantotenoylcysteine Synthetase Activity.

Authors:  Konrad J Mostert; Nandini Sharma; Marianne van der Zwaag; Roxine Staats; Lizbé Koekemoer; Ruchi Anand; Ody C M Sibon; Erick Strauss
Journal:  ACS Chem Biol       Date:  2021-09-28       Impact factor: 5.100
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.